Rapid Micro Biosystems (RPID) Competitors

Rapid Micro Biosystems logo
$0.74 0.00 (-0.54%)
As of 03:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.

RPID vs. MXCT, CDXS, SEER, CSBR, and IBAC

Should you buy Rapid Micro Biosystems stock or one of its competitors? Rapid Micro Biosystems's main competitors and comparable companies include MaxCyte (MXCT), Codexis (CDXS), Seer (SEER), Champions Oncology (CSBR), and IB Acquisition (IBAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Rapid Micro Biosystems compare to MaxCyte?

Rapid Micro Biosystems (NASDAQ:RPID) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Rapid Micro Biosystems has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Rapid Micro Biosystems currently has a consensus price target of $1.81, suggesting a potential upside of 146.26%. MaxCyte has a consensus price target of $4.50, suggesting a potential upside of 282.98%. Given MaxCyte's higher probable upside, analysts plainly believe MaxCyte is more favorable than Rapid Micro Biosystems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rapid Micro Biosystems
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
MaxCyte
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Rapid Micro Biosystems had 9 more articles in the media than MaxCyte. MarketBeat recorded 11 mentions for Rapid Micro Biosystems and 2 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.68 beat Rapid Micro Biosystems' score of -0.30 indicating that MaxCyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rapid Micro Biosystems
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
MaxCyte
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MaxCyte has lower revenue, but higher earnings than Rapid Micro Biosystems. MaxCyte is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rapid Micro Biosystems$33.59M1.10-$47.12M-$1.12N/A
MaxCyte$33.03M3.67-$44.63M-$0.26N/A

52.6% of Rapid Micro Biosystems shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 12.7% of Rapid Micro Biosystems shares are held by company insiders. Comparatively, 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MaxCyte has a net margin of -81.40% compared to Rapid Micro Biosystems' net margin of -145.56%. MaxCyte's return on equity of -15.05% beat Rapid Micro Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Rapid Micro Biosystems-145.56% -177.04% -73.12%
MaxCyte -81.40%-15.05%-12.79%

Summary

MaxCyte beats Rapid Micro Biosystems on 9 of the 14 factors compared between the two stocks.

How does Rapid Micro Biosystems compare to Codexis?

Codexis (NASDAQ:CDXS) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

In the previous week, Codexis had 3 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 14 mentions for Codexis and 11 mentions for Rapid Micro Biosystems. Codexis' average media sentiment score of 0.59 beat Rapid Micro Biosystems' score of -0.30 indicating that Codexis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Codexis
2 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rapid Micro Biosystems
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

78.5% of Codexis shares are held by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Codexis has a net margin of -21.77% compared to Rapid Micro Biosystems' net margin of -145.56%. Codexis' return on equity of -45.54% beat Rapid Micro Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Codexis-21.77% -45.54% -14.53%
Rapid Micro Biosystems -145.56%-177.04%-73.12%

Codexis presently has a consensus price target of $6.00, indicating a potential upside of 468.72%. Rapid Micro Biosystems has a consensus price target of $1.81, indicating a potential upside of 146.26%. Given Codexis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Codexis is more favorable than Rapid Micro Biosystems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Codexis
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Rapid Micro Biosystems
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Codexis has higher revenue and earnings than Rapid Micro Biosystems. Codexis is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codexis$70.39M1.64-$43.97M-$0.20N/A
Rapid Micro Biosystems$33.59M1.10-$47.12M-$1.12N/A

Codexis has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Rapid Micro Biosystems has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Summary

Codexis beats Rapid Micro Biosystems on 14 of the 16 factors compared between the two stocks.

How does Rapid Micro Biosystems compare to Seer?

Seer (NASDAQ:SEER) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Seer currently has a consensus price target of $4.00, suggesting a potential upside of 173.97%. Rapid Micro Biosystems has a consensus price target of $1.81, suggesting a potential upside of 146.26%. Given Seer's stronger consensus rating and higher probable upside, research analysts plainly believe Seer is more favorable than Rapid Micro Biosystems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seer
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
2 Strong Buy rating(s)
3.00
Rapid Micro Biosystems
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Rapid Micro Biosystems has a net margin of -145.56% compared to Seer's net margin of -450.86%. Seer's return on equity of -27.03% beat Rapid Micro Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Seer-450.86% -27.03% -23.80%
Rapid Micro Biosystems -145.56%-177.04%-73.12%

Rapid Micro Biosystems has higher revenue and earnings than Seer. Seer is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seer$16.58M4.88-$73.60M-$1.15N/A
Rapid Micro Biosystems$33.59M1.10-$47.12M-$1.12N/A

Seer has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Rapid Micro Biosystems has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, Rapid Micro Biosystems had 2 more articles in the media than Seer. MarketBeat recorded 11 mentions for Rapid Micro Biosystems and 9 mentions for Seer. Seer's average media sentiment score of 0.49 beat Rapid Micro Biosystems' score of -0.30 indicating that Seer is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Seer
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Rapid Micro Biosystems
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

75.2% of Seer shares are owned by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Rapid Micro Biosystems beats Seer on 9 of the 17 factors compared between the two stocks.

How does Rapid Micro Biosystems compare to Champions Oncology?

Champions Oncology (NASDAQ:CSBR) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Champions Oncology has a net margin of -1.82% compared to Rapid Micro Biosystems' net margin of -145.56%. Champions Oncology's return on equity of -25.77% beat Rapid Micro Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology-1.82% -25.77% -3.71%
Rapid Micro Biosystems -145.56%-177.04%-73.12%

Rapid Micro Biosystems has a consensus target price of $1.81, indicating a potential upside of 146.26%. Given Rapid Micro Biosystems' stronger consensus rating and higher possible upside, analysts plainly believe Rapid Micro Biosystems is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Rapid Micro Biosystems
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Champions Oncology has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Rapid Micro Biosystems has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

In the previous week, Rapid Micro Biosystems had 10 more articles in the media than Champions Oncology. MarketBeat recorded 11 mentions for Rapid Micro Biosystems and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.88 beat Rapid Micro Biosystems' score of -0.30 indicating that Champions Oncology is being referred to more favorably in the media.

Company Overall Sentiment
Champions Oncology Very Positive
Rapid Micro Biosystems Neutral

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 46.3% of Champions Oncology shares are owned by insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Champions Oncology has higher revenue and earnings than Rapid Micro Biosystems. Champions Oncology is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$59.42M1.08-$1.17M-$0.08N/A
Rapid Micro Biosystems$33.59M1.10-$47.12M-$1.12N/A

Summary

Champions Oncology and Rapid Micro Biosystems tied by winning 8 of the 16 factors compared between the two stocks.

How does Rapid Micro Biosystems compare to IB Acquisition?

Rapid Micro Biosystems (NASDAQ:RPID) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

In the previous week, Rapid Micro Biosystems had 10 more articles in the media than IB Acquisition. MarketBeat recorded 11 mentions for Rapid Micro Biosystems and 1 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 1.79 beat Rapid Micro Biosystems' score of -0.30 indicating that IB Acquisition is being referred to more favorably in the news media.

Company Overall Sentiment
Rapid Micro Biosystems Neutral
IB Acquisition Very Positive

IB Acquisition has lower revenue, but higher earnings than Rapid Micro Biosystems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rapid Micro Biosystems$33.59M1.10-$47.12M-$1.12N/A
IB AcquisitionN/AN/AN/AN/AN/A

52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 12.7% of Rapid Micro Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rapid Micro Biosystems currently has a consensus price target of $1.81, suggesting a potential upside of 146.26%. Given Rapid Micro Biosystems' stronger consensus rating and higher probable upside, equities analysts clearly believe Rapid Micro Biosystems is more favorable than IB Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rapid Micro Biosystems
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
IB Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

IB Acquisition has a net margin of 0.00% compared to Rapid Micro Biosystems' net margin of -145.56%. IB Acquisition's return on equity of 0.00% beat Rapid Micro Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Rapid Micro Biosystems-145.56% -177.04% -73.12%
IB Acquisition N/A N/A N/A

Summary

Rapid Micro Biosystems beats IB Acquisition on 7 of the 11 factors compared between the two stocks.

Get Rapid Micro Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for RPID and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RPID vs. The Competition

MetricRapid Micro BiosystemsLife Sciences Tools & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$36.92M$10.75B$7.73B$11.61B
Dividend YieldN/A1.45%2.46%4.43%
P/E Ratio-0.6651.1134.1629.83
Price / Sales1.108.328.475.65
Price / CashN/A26.6921.9322.50
Price / Book0.984.444.373.65
Net Income-$47.12M$57.48B$3.52B$392.18M
7 Day Performance-2.31%-4.95%-5.48%-4.27%
1 Month Performance-3.72%-1.10%-4.62%-6.75%
1 Year Performance-82.22%20.66%-1.57%-7.22%

Rapid Micro Biosystems Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RPID
Rapid Micro Biosystems
2.9873 of 5 stars
$0.74
-0.5%
$1.81
+146.3%
-82.4%$36.92M$33.59MN/A171
MXCT
MaxCyte
3.564 of 5 stars
$1.13
-13.1%
$5.00
+342.5%
-25.3%$134.17M$33.03MN/A91
CDXS
Codexis
3.4624 of 5 stars
$1.00
-9.9%
$6.50
+550.0%
-35.6%$121.55M$70.39MN/A146
SEER
Seer
3.7036 of 5 stars
$1.61
-4.2%
$4.00
+148.4%
-26.0%$93.03M$16.58MN/A124
CSBR
Champions Oncology
0.7488 of 5 stars
$4.75
-1.9%
N/A-32.2%$67.37M$59.42MN/A214

Related Companies and Tools


This page (NASDAQ:RPID) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners